‘Restart economy sooner than later’
India is likely to recover faster than the rest of the world from the economic turmoil caused by Covid-19, with new opportunities presenting themselves, says Biocon chairperson.
kiran mazumdar shaw
April 2020
February 2020
January 2020
November 2019
October 2019
September 2019
SC agrees to amend order making Covid-19 tests free
An earlier judgment by the apex court making Coronavirus tests free across the board had sparked concerns over the viability of the private sector’s participation in testing for the virus.
Shaw named EY Entrepreneur of the Year
The award recognises entrepreneurs who, with their disruptive ideas and passion for growth, are creating successful global enterprises.
Budget: Where is the short-term boost, asks India Inc.
The Budget rightly focusses on rural and agrarian growth, infrastructure creation, and a digital future, but misses out on a much-needed consumption boost.
True North invests ₹536 crore in Biocon arm
The private equity firm’s investment values Biocon Biologics at about $3 billion on a pre-money equity basis.
Fortune India 500: Why are there so few women leaders?
Only around 6% companies on the Fortune India 500 list are managed by women.
MPW Summit 2019: Celebrating women power
The Fortune India MPW summit brings some of India’s biggest women executives together to discuss ideas and issues related to gender, women in the workplace, the economy, and the society at large.
Biocon’s biologics portfolio comes into its own
Bengaluru-based Biocon’s portfolio of biologic drugs has grown rapidly in the last five years and the company wants it to be a $1 billion business by 2022.
Inside the issue: Most Powerful Women
Zia Mody, co-founder, AZB & Partners, tops this year’s Most Powerful Women in Business list, Kiran Mazumdar-Shaw, India’s biotech queen, is at No. 2. Here’s more about the list.
B.R. Shetty: Prescribing growth
B.R. Shetty plans to pump in billions of dollars as part of his plan to open 20,000 hospital beds in India over the next 10 years. Given the churn in the healthcare sector, will he succeed?
